Orthofix Medical (OFIX) Financials

$12.21 +0.03 (+0.25%)

Closing price 05/13/2026 04:00 PM Eastern

Extended Trading

$12.21 +0.00 (+0.01%)

As of 04:06 AM Eastern

Annual Income Statements for Orthofix Medical

This table shows Orthofix Medical's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	-20	-151	-126
Consolidated Net Income / (Loss)	-20	-151	-126
Net Income / (Loss) Continuing Operations	-20	-151	-126
Total Pre-Tax Income	-18	-149	-124
Total Operating Income	-13	-139	-85
Total Gross Profit	337	486	546
Total Revenue	461	745	799
Operating Revenue	461	745	799
Total Cost of Revenue	124	260	254
Operating Cost of Revenue	124	260	254
Total Operating Expenses	350	625	631
Selling, General & Admin Expense	309	530	533
Research & Development Expense	49	80	74
Amortization Expense	-7.40	15	24
Total Other Income / (Expense), net	-4.44	-9.57	-39
Interest Expense	1.29	8.63	30
Other Income / (Expense), net	-3.15	-0.94	-9.63
Income Tax Expense	2.04	2.72	2.12
Basic Earnings per Share	($0.98)	($4.12)	($3.30)
Weighted Average Basic Shares Outstanding	20.05M	36.73M	38.13M
Diluted Earnings per Share	($0.98)	($4.12)	($3.30)
Weighted Average Diluted Shares Outstanding	20.05M	36.73M	38.13M
Weighted Average Basic & Diluted Shares Outstanding	36.46M	37.41M	39.02M

This table shows Orthofix Medical's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	-11	-7.06	-61	-39	-29	-22	-36	-33	-27	-29
Consolidated Net Income / (Loss)	-11	-7.06	-61	-39	-29	-22	-36	-33	-27	-29
Net Income / (Loss) Continuing Operations	-11	-7.06	-61	-39	-29	-22	-36	-33	-27	-29
Total Pre-Tax Income	-9.37	-6.99	-60	-38	-28	-22	-35	-32	-27	-30
Total Operating Income	-5.79	-11	-60	-37	-24	-18	-29	-25	-19	-11
Total Gross Profit	83	89	110	120	120	137	127	135	135	149
Total Revenue	114	122	175	187	184	199	189	199	197	216
Operating Revenue	114	122	175	187	184	199	189	199	197	216
Total Cost of Revenue	31	33	65	67	64	64	61	64	62	67
Operating Cost of Revenue	31	33	65	67	64	64	61	64	62	67
Total Operating Expenses	89	100	170	156	144	155	157	160	154	160
Selling, General & Admin Expense	19	254	49	34	27	420	32	34	34	433
Research & Development Expense	12	13	23	19	19	19	19	18	17	19
Amortization Expense	2.48	2.27	4.13	3.33	3.57	3.72	5.40	7.39	6.52	5.03
Total Other Income / (Expense), net	-3.59	4.06	-0.61	-1.29	-3.94	-3.73	-5.83	-7.45	-7.74	-18
Interest Expense	0.28	0.23	1.29	1.27	1.58	4.50	4.56	4.94	5.21	15
Other Income / (Expense), net	-3.31	4.29	0.68	-0.02	-2.36	0.77	-1.27	-2.51	-2.53	-3.31
Income Tax Expense	1.34	0.08	0.61	1.51	0.47	0.13	0.85	1.08	0.75	-0.56
Basic Earnings per Share	($0.53)	($0.35)	($1.71)	($1.07)	($0.77)	($0.57)	($0.95)	($0.88)	($0.71)	($0.76)
Weighted Average Basic Shares Outstanding	20.09M	20.05M	35.73M	36.76M	37.25M	36.73M	37.74M	38.02M	38.49M	38.13M
Diluted Earnings per Share	($0.53)	($0.35)	($1.71)	($1.07)	($0.77)	($0.57)	($0.95)	($0.88)	($0.71)	($0.76)
Weighted Average Diluted Shares Outstanding	20.09M	20.05M	35.73M	36.76M	37.25M	36.73M	37.74M	38.02M	38.49M	38.13M
Weighted Average Basic & Diluted Shares Outstanding	20.01M	36.46M	36.54M	36.74M	36.76M	37.41M	37.53M	38.17M	38.21M	39.02M

This table details how cash moves in and out of Orthofix Medical's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Net Change in Cash & Equivalents	-37	-13	48
Net Cash From Operating Activities	-12	-46	26
Net Cash From Continuing Operating Activities	-12	-46	26
Net Income / (Loss) Continuing Operations	-20	-151	-126
Consolidated Net Income / (Loss)	-20	-151	-126
Depreciation Expense	29	53	60
Amortization Expense	3.06	44	28
Non-Cash Adjustments To Reconcile Net Income	37	65	74
Changes in Operating Assets and Liabilities, net	-61	-56	-10
Net Cash From Investing Activities	-25	-33	-28
Net Cash From Continuing Investing Activities	-25	-33	-28
Purchase of Property, Plant & Equipment	-23	-62	-35
Acquisitions	-1.50	0.00	0.00
Divestitures	0.00	29	0.00
Sale and/or Maturity of Investments	0.13	0.00	7.40
Other Investing Activities, net	0.00	-0.50	-0.10
Net Cash From Financing Activities	-0.08	65	51
Net Cash From Continuing Financing Activities	-0.08	65	51
Repayment of Debt	-0.09	-82	-146
Payment of Dividends	0.00	-27	0.00
Issuance of Debt	0.00	175	198
Issuance of Common Equity	4.34	5.13	6.26
Other Financing Activities, net	-4.32	-5.05	-7.02
Effect of Exchange Rate Changes	-1.00	0.62	-0.94

This table details how cash moves in and out of Orthofix Medical's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Change in Cash & Equivalents	-7.88	-0.96	-0.73	-12	-3.94	4.09	-8.29	-0.60	3.69	53
Net Cash From Operating Activities	-1.26	2.35	-34	-5.52	0.48	-6.69	-19	8.98	12	24
Net Cash From Continuing Operating Activities	-1.26	2.35	-34	-5.52	0.48	-6.69	-19	8.98	12	24
Net Income / (Loss) Continuing Operations	-11	-7.06	-61	-39	-29	-22	-36	-33	-27	-29
Consolidated Net Income / (Loss)	-11	-7.06	-61	-39	-29	-22	-36	-33	-27	-29
Depreciation Expense	7.57	7.42	13	13	13	14	15	14	15	16
Amortization Expense	0.75	0.74	13	11	9.11	10	4.53	4.56	4.66	14
Non-Cash Adjustments To Reconcile Net Income	8.58	11	20	23	15	7.07	18	25	17	14
Changes in Operating Assets and Liabilities, net	-7.45	-9.44	-19	-13	-7.97	-16	-20	-1.32	2.21	8.39
Net Cash From Investing Activities	-5.47	-5.90	17	-13	-22	-15	-11	-9.72	-5.86	-1.14
Net Cash From Continuing Investing Activities	-5.47	-5.90	17	-13	-22	-15	-11	-9.72	-5.86	-1.14
Purchase of Property, Plant & Equipment	-5.13	-7.00	-11	-12	-22	-16	-11	-9.34	-5.32	-9.67
Acquisitions	-0.43	1.10	-0.36	-0.47	-0.47	1.30	-0.27	-0.37	-0.49	1.14
Net Cash From Financing Activities	-0.25	1.50	16	5.81	18	25	21	0.23	-2.46	31
Net Cash From Continuing Financing Activities	-0.25	1.50	16	5.81	18	25	21	0.23	-2.46	31
Repayment of Debt	-0.02	-0.02	-27	-0.28	-0.42	-55	-17	-0.85	-0.23	-129
Issuance of Debt	-	-	45	6.00	19	105	40	-	-	158
Issuance of Common Equity	-	1.94	0.00	2.38	-	2.75	0.00	3.19	0.12	2.95
Other Financing Activities, net	-0.23	-0.42	-2.12	-2.29	-0.33	-0.31	-2.00	-2.12	-2.35	-0.55
Effect of Exchange Rate Changes	-0.89	1.09	0.22	0.17	-0.33	0.56	-0.28	-0.09	0.34	-0.90

This table presents Orthofix Medical's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Total Assets	459	925	893
Total Current Assets	256	420	433
Cash & Equivalents	51	33	83
Restricted Cash	0.00	4.65	2.50
Accounts Receivable	83	128	135
Inventories, net	100	222	189
Prepaid Expenses	22	32	23
Plant, Property, & Equipment, net	58	159	140
Total Noncurrent Assets	144	346	320
Goodwill	71	195	195
Intangible Assets	47	117	99
Other Noncurrent Operating Assets	26	33	26
Total Liabilities & Shareholders' Equity	459	925	893
Total Liabilities	122	327	390
Total Current Liabilities	84	165	169
Short-Term Debt	0.00	1.25	0.00
Accounts Payable	28	58	49
Other Current Liabilities	56	106	120
Total Noncurrent Liabilities	38	161	222
Long-Term Debt	0.00	93	157
Other Noncurrent Operating Liabilities	38	68	65
Commitments & Contingencies	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	337	599	503
Total Preferred & Common Equity	337	599	503
Total Common Equity	337	599	503
Common Stock	337	750	784
Retained Earnings	1.25	-150	-276
Accumulated Other Comprehensive Income / (Loss)	-1.38	-1.29	-4.30

This table presents Orthofix Medical's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Period end date	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024
Total Assets	450	917	901	906	906	882	868
Total Current Assets	247	410	399	394	399	386	386
Cash & Equivalents	52	50	38	34	27	26	30
Restricted Cash	-	-	-	-	2.50	2.50	2.50
Accounts Receivable	76	113	112	114	126	125	125
Inventories, net	100	222	222	222	219	210	206
Prepaid Expenses	19	25	27	24	25	22	23
Plant, Property, & Equipment, net	58	137	141	153	158	154	147
Total Noncurrent Assets	145	370	361	359	349	342	335
Goodwill	71	203	192	195	195	195	195
Intangible Assets	48	122	126	121	113	108	105
Noncurrent Deferred & Refundable Income Taxes	1.54	0.00	0.00	0.00	0.00	0.00	0.00
Other Noncurrent Operating Assets	25	45	44	43	41	39	35
Total Liabilities & Shareholders' Equity	450	917	901	906	906	882	868
Total Liabilities	116	253	261	290	336	336	342
Total Current Liabilities	78	138	142	153	151	156	162
Short-Term Debt	-	-	-	-	3.13	4.69	6.25
Accounts Payable	28	46	51	53	57	50	47
Other Current Liabilities	50	92	90	99	90	101	109
Total Noncurrent Liabilities	38	115	119	138	185	180	180
Long-Term Debt	-	45	51	70	115	113	112
Other Noncurrent Operating Liabilities	38	70	68	68	70	67	68
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	334	664	640	615	570	546	526
Total Preferred & Common Equity	334	664	640	615	570	546	526
Total Common Equity	334	664	640	615	570	546	526
Common Stock	330	725	739	745	757	768	774
Retained Earnings	8.31	-60	-99	-128	-186	-220	-247
Accumulated Other Comprehensive Income / (Loss)	-5.16	-0.95	-0.11	-1.86	-0.66	-2.73	-0.90

This table displays calculated financial ratios and metrics derived from Orthofix Medical's official financial filings.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Growth Metrics	-	-	-
Revenue Growth	-0.81%	61.77%	7.27%
EBITDA Growth	-26.96%	-377.47%	85.97%
EBIT Growth	-40.83%	-753.02%	32.71%
NOPAT Growth	-59.57%	-948.46%	39.17%
Net Income Growth	48.54%	-666.60%	16.78%
EPS Growth	49.74%	-320.41%	19.90%
Operating Cash Flow Growth	-162.45%	-296.54%	156.37%
Free Cash Flow Firm Growth	-1,002.75%	-906.34%	104.65%
Invested Capital Growth	14.88%	129.01%	-12.35%
Revenue Q/Q Growth	-0.61%	11.50%	2.12%
EBITDA Q/Q Growth	16.95%	10.42%	59.89%
EBIT Q/Q Growth	12.80%	-8.35%	2.84%
NOPAT Q/Q Growth	-14.61%	-5.52%	7.48%
Net Income Q/Q Growth	56.59%	-11.09%	-5.86%
EPS Q/Q Growth	60.96%	-5.64%	-6.11%
Operating Cash Flow Q/Q Growth	-447.60%	-24.63%	656.54%
Free Cash Flow Firm Q/Q Growth	-454.23%	-0.93%	190.27%
Invested Capital Q/Q Growth	1.52%	0.54%	-6.12%
Profitability Metrics	-	-	-
Gross Margin	73.18%	65.24%	68.28%
EBITDA Margin	3.40%	-5.83%	-0.76%
Operating Margin	-2.88%	-18.66%	-10.58%
EBIT Margin	-3.56%	-18.79%	-11.79%
Profit (Net Income) Margin	-4.29%	-20.31%	-15.76%
Tax Burden Percent	111.54%	101.88%	101.71%
Interest Burden Percent	107.85%	106.10%	131.44%
Effective Tax Rate	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-3.47%	-20.69%	-9.63%
ROIC Less NNEP Spread (ROIC-NNEP)	11.63%	-1,851.80%	-114.05%
Return on Net Nonoperating Assets (RNNOA)	-2.39%	-11.68%	-13.24%
Return on Equity (ROE)	-5.86%	-32.36%	-22.87%
Cash Return on Invested Capital (CROIC)	-17.32%	-99.11%	3.53%
Operating Return on Assets (OROA)	-3.51%	-20.24%	-10.36%
Return on Assets (ROA)	-4.22%	-21.88%	-13.86%
Return on Common Equity (ROCE)	-5.86%	-32.36%	-22.87%
Return on Equity Simple (ROE_SIMPLE)	-5.86%	-25.29%	-25.04%
Net Operating Profit after Tax (NOPAT)	-9.29	-97	-59
NOPAT Margin	-2.02%	-13.07%	-7.41%
Net Nonoperating Expense Percent (NNEP)	-15.10%	1,831.12%	104.42%
Return On Investment Capital (ROIC_SIMPLE)	-2.76%	-14.05%	-8.97%
Cost of Revenue to Revenue	26.82%	34.93%	31.72%
SG&A Expenses to Revenue	67.02%	71.16%	66.61%
R&D to Revenue	10.65%	10.76%	9.21%
Operating Expenses to Revenue	76.06%	83.91%	78.86%
Earnings before Interest and Taxes (EBIT)	-16	-140	-94
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	16	-43	-6.09
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	1.22	0.83	1.33
Price to Tangible Book Value (P/TBV)	1.88	1.73	3.19
Price to Revenue (P/Rev)	0.89	0.66	0.83
Price to Earnings (P/E)	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	1.26	0.84	1.29
Enterprise Value to Revenue (EV/Rev)	0.78	0.74	0.92
Enterprise Value to EBITDA (EV/EBITDA)	23.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	28.64
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	34.04
Leverage & Solvency	-	-	-
Debt to Equity	0.00	0.16	0.31
Long-Term Debt to Equity	0.00	0.16	0.31
Financial Leverage	-0.21	0.01	0.12
Leverage Ratio	1.39	1.48	1.65
Compound Leverage Factor	1.50	1.57	2.17
Debt to Total Capital	0.00%	13.61%	23.79%
Short-Term Debt to Total Capital	0.00%	0.18%	0.00%
Long-Term Debt to Total Capital	0.00%	13.43%	23.79%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	86.39%	76.21%
Debt to EBITDA	0.00	-2.17	-25.77
Net Debt to EBITDA	0.00	-1.30	-11.70
Long-Term Debt to EBITDA	0.00	-2.14	-25.77
Debt to NOPAT	0.00	-0.97	-2.65
Net Debt to NOPAT	0.00	-0.58	-1.20
Long-Term Debt to NOPAT	0.00	-0.96	-2.65
Altman Z-Score	3.37	1.32	1.50
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-
Current Ratio	3.06	2.54	2.57
Quick Ratio	1.60	0.98	1.29
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	-46	-467	22
Operating Cash Flow to CapEx	-49.82%	-73.74%	73.95%
Free Cash Flow to Firm to Interest Expense	-35.99	-54.05	0.73
Operating Cash Flow to Interest Expense	-8.96	-5.30	0.87
Operating Cash Flow Less CapEx to Interest Expense	-26.94	-12.49	-0.31
Efficiency Ratios	-	-	-
Asset Turnover	0.99	1.08	0.88
Accounts Receivable Turnover	5.71	7.07	6.08
Inventory Turnover	1.35	1.62	1.23
Fixed Asset Turnover	7.84	6.86	5.35
Accounts Payable Turnover	4.57	6.06	4.73
Days Sales Outstanding (DSO)	63.94	51.66	59.99
Days Inventory Outstanding (DIO)	270.51	225.92	296.21
Days Payable Outstanding (DPO)	79.85	60.25	77.11
Cash Conversion Cycle (CCC)	254.60	217.33	279.09
Capital & Investment Metrics	-	-	-
Invested Capital	286	655	574
Invested Capital Turnover	1.72	1.58	1.30
Increase / (Decrease) in Invested Capital	37	369	-81
Enterprise Value (EV)	360	552	738
Market Capitalization	411	495	667
Book Value per Share	$16.84	$16.29	$13.17
Tangible Book Value per Share	$10.90	$7.79	$5.48
Total Capital	337	693	660
Total Debt	0.00	94	157
Total Long-Term Debt	0.00	93	157
Net Debt	-51	57	71
Capital Expenditures (CapEx)	23	62	35
Debt-free, Cash-free Net Working Capital (DFCFNWC)	122	219	179
Debt-free Net Working Capital (DFNWC)	172	256	265
Net Working Capital (NWC)	172	255	265
Net Nonoperating Expense (NNE)	10	54	67
Net Nonoperating Obligations (NNO)	-51	57	71
Total Depreciation and Amortization (D&A)	32	97	88
Debt-free, Cash-free Net Working Capital to Revenue	26.41%	29.35%	22.38%
Debt-free Net Working Capital to Revenue	37.41%	34.41%	33.10%
Net Working Capital to Revenue	37.41%	34.24%	33.10%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	($0.98)	($4.12)	($3.30)
Adjusted Weighted Average Basic Shares Outstanding	20.05M	36.73M	38.13M
Adjusted Diluted Earnings per Share	($0.98)	($4.12)	($3.30)
Adjusted Weighted Average Diluted Shares Outstanding	20.05M	36.73M	38.13M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	36.46M	37.41M	39.02M
Normalized Net Operating Profit after Tax (NOPAT)	-9.29	-97	-59
Normalized NOPAT Margin	-2.02%	-13.07%	-7.41%
Pre Tax Income Margin	-3.84%	-19.94%	-15.49%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	-12.75	-16.23	-3.18
NOPAT to Interest Expense	-7.21	-11.28	-2.00
EBIT Less CapEx to Interest Expense	-30.73	-23.42	-4.36
NOPAT Less CapEx to Interest Expense	-25.19	-18.47	-3.18
Payout Ratios	-	-	-
Dividend Payout Ratio	0.00%	-17.77%	0.00%
Augmented Payout Ratio	0.00%	-17.77%	0.00%

This table displays calculated financial ratios and metrics derived from Orthofix Medical's official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	1.39%	-2.27%	64.64%	58.39%	61.41%	62.88%	7.65%	6.20%	6.85%	8.33%
EBITDA Growth	-113.03%	260.51%	-868.28%	-214.19%	-497.15%	361.37%	66.02%	27.94%	65.42%	141.10%
EBIT Growth	-332.68%	26.29%	-1,370.80%	-1,162.68%	-194.77%	-159.68%	48.15%	25.20%	20.08%	15.72%
NOPAT Growth	-1,748.88%	-18.08%	-1,840.03%	-571.91%	-322.48%	-65.84%	50.87%	32.01%	22.70%	37.34%
Net Income Growth	-393.60%	78.48%	-1,266.32%	-1,684.01%	-169.29%	-213.99%	40.89%	15.18%	5.09%	-31.44%
EPS Growth	-581.82%	81.38%	-677.27%	-991.67%	-45.28%	-62.86%	44.44%	17.76%	7.79%	-33.33%
Operating Cash Flow Growth	-119.65%	-80.07%	-341.30%	-12.27%	137.74%	-385.09%	45.34%	262.87%	2,346.75%	454.50%
Free Cash Flow Firm Growth	40.45%	-1,116.21%	-7,126.73%	-8,387.33%	-8,876.44%	-752.59%	95.34%	100.20%	106.91%	119.08%
Invested Capital Growth	0.09%	14.88%	150.02%	131.36%	131.24%	129.01%	-0.02%	-2.79%	-6.13%	-12.35%
Revenue Q/Q Growth	-3.45%	7.22%	43.34%	6.74%	-1.61%	8.19%	-5.26%	5.31%	-1.01%	9.69%
EBITDA Q/Q Growth	-107.19%	281.32%	-2,463.09%	62.91%	62.43%	240.10%	-274.02%	21.34%	81.97%	1,076.82%
EBIT Q/Q Growth	-363.70%	25.70%	-773.60%	37.92%	26.86%	34.54%	-74.43%	10.44%	21.84%	30.97%
NOPAT Q/Q Growth	-174.55%	-90.84%	-440.69%	38.65%	33.26%	25.09%	-60.18%	15.10%	24.12%	39.27%
Net Income Q/Q Growth	-530.53%	34.10%	-762.90%	35.30%	26.81%	23.16%	-62.44%	7.15%	18.11%	-6.42%
EPS Q/Q Growth	-541.67%	33.96%	-388.57%	37.43%	28.04%	25.97%	-66.67%	7.37%	19.32%	-7.04%
Operating Cash Flow Q/Q Growth	74.27%	285.76%	-1,548.89%	83.79%	108.65%	-1,503.35%	-177.79%	148.31%	29.91%	103.32%
Free Cash Flow Firm Q/Q Growth	-190.10%	-939.07%	-876.11%	9.31%	2.41%	1.31%	94.66%	103.94%	3,232.80%	172.45%
Invested Capital Q/Q Growth	-0.19%	1.52%	130.36%	-0.88%	-0.24%	0.54%	0.57%	-3.63%	-3.67%	-6.12%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	73.18%	72.96%	62.97%	63.93%	65.09%	68.63%	67.46%	67.84%	68.69%	69.02%
EBITDA Margin	-0.68%	1.14%	-18.86%	-6.55%	-2.50%	3.24%	-5.95%	-4.45%	-0.81%	7.21%
Operating Margin	-5.08%	-9.04%	-34.08%	-19.59%	-13.29%	-9.20%	-15.55%	-12.54%	-9.61%	-5.32%
EBIT Margin	-7.98%	-5.53%	-33.70%	-19.60%	-14.57%	-8.82%	-16.23%	-13.80%	-10.90%	-6.86%
Profit (Net Income) Margin	-9.40%	-5.78%	-34.78%	-21.08%	-15.68%	-11.14%	-19.10%	-16.84%	-13.93%	-13.52%
Tax Burden Percent	114.34%	101.07%	101.01%	103.98%	101.66%	100.95%	102.42%	103.35%	102.82%	98.10%
Interest Burden Percent	103.05%	103.39%	102.18%	103.45%	105.88%	125.17%	114.89%	118.03%	124.32%	200.88%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-5.85%	-10.89%	-27.38%	-17.54%	-13.32%	-10.20%	-12.53%	-10.50%	-8.34%	-4.84%
ROIC Less NNEP Spread (ROIC-NNEP)	4.04%	-11.85%	22.41%	42.21%	139.95%	-327.26%	-49.50%	-41.72%	-31.50%	-37.86%
Return on Net Nonoperating Assets (RNNOA)	-0.78%	2.44%	-1.72%	-1.98%	-2.26%	-2.06%	-3.36%	-3.61%	-3.37%	-4.39%
Return on Equity (ROE)	-6.63%	-8.45%	-29.10%	-19.52%	-15.58%	-12.26%	-15.89%	-14.10%	-11.71%	-9.24%
Cash Return on Invested Capital (CROIC)	-2.97%	-17.32%	-96.32%	-96.22%	-99.01%	-99.11%	-11.53%	-7.71%	-3.80%	3.53%
Operating Return on Assets (OROA)	-7.79%	-5.45%	-25.87%	-17.21%	-14.37%	-9.49%	-13.51%	-11.93%	-9.62%	-6.03%
Return on Assets (ROA)	-9.17%	-5.69%	-26.71%	-18.51%	-15.47%	-12.00%	-15.89%	-14.55%	-12.30%	-11.88%
Return on Common Equity (ROCE)	-6.63%	-8.45%	-29.10%	-19.52%	-15.58%	-12.26%	-15.89%	-14.10%	-11.71%	-9.24%
Return on Equity Simple (ROE_SIMPLE)	-13.64%	0.00%	-11.48%	-18.46%	-22.14%	0.00%	-22.18%	-22.07%	-22.63%	0.00%
Net Operating Profit after Tax (NOPAT)	-4.05	-7.73	-42	-26	-17	-13	-21	-17	-13	-8.03
NOPAT Margin	-3.55%	-6.32%	-23.86%	-13.71%	-9.30%	-6.44%	-10.89%	-8.78%	-6.73%	-3.73%
Net Nonoperating Expense Percent (NNEP)	-9.88%	0.97%	-49.78%	-59.74%	-153.27%	317.07%	36.97%	31.23%	23.16%	33.02%
Return On Investment Capital (ROIC_SIMPLE)	-	-2.30%	-	-	-	-1.85%	-	-	-	-1.22%
Cost of Revenue to Revenue	26.82%	27.04%	37.03%	36.07%	34.91%	32.04%	32.54%	32.16%	31.31%	30.98%
SG&A Expenses to Revenue	16.95%	208.04%	27.86%	18.27%	14.75%	211.11%	16.78%	17.12%	17.07%	200.93%
R&D to Revenue	10.48%	10.76%	13.30%	10.39%	10.09%	9.51%	10.33%	9.09%	8.80%	8.72%
Operating Expenses to Revenue	78.26%	81.99%	97.05%	83.51%	78.37%	77.83%	83.02%	80.38%	78.30%	74.34%
Earnings before Interest and Taxes (EBIT)	-9.10	-6.76	-59	-37	-27	-18	-31	-27	-21	-15
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-0.77	1.40	-33	-12	-4.60	6.45	-11	-8.83	-1.59	16
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	1.15	1.22	0.92	1.03	0.77	0.83	0.95	0.91	1.13	1.33
Price to Tangible Book Value (P/TBV)	1.78	1.88	1.80	2.05	1.58	1.73	2.07	2.05	2.63	3.19
Price to Revenue (P/Rev)	0.82	0.89	1.15	1.10	0.71	0.66	0.72	0.65	0.76	0.83
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	1.17	1.26	0.92	1.03	0.78	0.84	0.96	0.92	1.12	1.29
Enterprise Value to Revenue (EV/Rev)	0.71	0.78	1.14	1.13	0.76	0.74	0.83	0.76	0.87	0.92
Enterprise Value to EBITDA (EV/EBITDA)	24.69	23.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	28.64
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	34.04
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.07	0.08	0.11	0.16	0.21	0.22	0.23	0.31
Long-Term Debt to Equity	0.00	0.00	0.07	0.08	0.11	0.16	0.20	0.21	0.21	0.31
Financial Leverage	-0.19	-0.21	-0.08	-0.05	-0.02	0.01	0.07	0.09	0.11	0.12
Leverage Ratio	1.36	1.39	1.38	1.39	1.43	1.48	1.48	1.50	1.55	1.65
Compound Leverage Factor	1.40	1.44	1.41	1.44	1.51	1.85	1.70	1.77	1.93	3.32
Debt to Total Capital	0.00%	0.00%	6.35%	7.38%	10.21%	13.61%	17.17%	17.77%	18.38%	23.79%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.18%	0.45%	0.71%	0.97%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	6.35%	7.38%	10.21%	13.43%	16.71%	17.07%	17.41%	23.79%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	93.65%	92.62%	89.79%	86.39%	82.83%	82.23%	81.62%	76.21%
Debt to EBITDA	0.00	0.00	-2.08	-1.14	-1.44	-2.17	-5.46	-6.48	-7.80	-25.77
Net Debt to EBITDA	0.00	0.00	0.23	-0.30	-0.75	-1.30	-4.10	-4.90	-5.65	-11.70
Long-Term Debt to EBITDA	0.00	0.00	-2.08	-1.14	-1.44	-2.14	-5.32	-6.22	-7.39	-25.77
Debt to NOPAT	0.00	0.00	-0.92	-0.64	-0.76	-0.97	-1.55	-1.74	-1.85	-2.65
Net Debt to NOPAT	0.00	0.00	0.10	-0.17	-0.39	-0.58	-1.17	-1.31	-1.34	-1.20
Long-Term Debt to NOPAT	0.00	0.00	-0.92	-0.64	-0.76	-0.96	-1.51	-1.67	-1.75	-2.65
Altman Z-Score	3.42	3.43	2.08	2.23	1.74	1.76	1.74	1.62	1.78	1.79
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	3.18	3.06	2.98	2.82	2.58	2.54	2.65	2.48	2.39	2.57
Quick Ratio	1.64	1.60	1.19	1.06	0.97	0.98	1.01	0.97	0.96	1.29
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-4.31	-45	-437	-397	-387	-382	-20	0.80	27	73
Operating Cash Flow to CapEx	-24.65%	33.54%	-296.55%	-44.66%	2.18%	-40.93%	-176.37%	96.15%	219.30%	245.47%
Free Cash Flow to Firm to Interest Expense	-15.57	-195.65	-339.28	-313.28	-245.59	-84.89	-4.47	0.16	5.14	4.89
Operating Cash Flow to Interest Expense	-4.56	10.25	-26.39	-4.36	0.30	-1.49	-4.08	1.82	2.24	1.59
Operating Cash Flow Less CapEx to Interest Expense	-23.07	-20.32	-35.29	-14.11	-13.58	-5.12	-6.39	-0.07	1.22	0.94
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.98	0.99	0.77	0.88	0.99	1.08	0.83	0.86	0.88	0.88
Accounts Receivable Turnover	6.41	5.71	5.70	6.32	7.05	7.07	6.35	6.48	6.55	6.08
Inventory Turnover	1.34	1.35	1.03	1.23	1.43	1.62	1.16	1.17	1.17	1.23
Fixed Asset Turnover	7.95	7.84	5.42	6.01	6.35	6.86	5.14	5.23	5.23	5.35
Accounts Payable Turnover	5.22	4.57	4.37	4.68	5.65	6.06	4.99	4.98	5.00	4.73
Days Sales Outstanding (DSO)	56.93	63.94	64.03	57.76	51.81	51.66	57.47	56.31	55.70	59.99
Days Inventory Outstanding (DIO)	272.77	270.51	354.24	297.68	255.92	225.92	313.34	311.66	311.40	296.21
Days Payable Outstanding (DPO)	69.96	79.85	83.58	77.92	64.58	60.25	73.20	73.29	73.07	77.11
Cash Conversion Cycle (CCC)	259.74	254.60	334.69	277.51	243.14	217.33	297.61	294.68	294.04	279.09
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	282	286	659	653	652	655	659	635	612	574
Invested Capital Turnover	1.65	1.72	1.15	1.28	1.43	1.58	1.15	1.20	1.24	1.30
Increase / (Decrease) in Invested Capital	0.26	37	396	371	370	369	-0.14	-18	-40	-81
Enterprise Value (EV)	331	360	606	673	509	552	632	587	682	738
Market Capitalization	382	411	611	660	472	495	543	498	596	667
Book Value per Share	$16.67	$16.84	$18.22	$17.51	$16.75	$16.29	$15.25	$14.55	$13.78	$13.17
Tangible Book Value per Share	$10.73	$10.90	$9.31	$8.82	$8.16	$7.79	$7.02	$6.47	$5.93	$5.48
Total Capital	334	337	709	691	685	693	689	664	644	660
Total Debt	0.00	0.00	45	51	70	94	118	118	118	157
Total Long-Term Debt	0.00	0.00	45	51	70	93	115	113	112	157
Net Debt	-52	-51	-4.97	13	36	57	89	89	86	71
Capital Expenditures (CapEx)	5.13	7.00	11	12	22	16	11	9.34	5.32	9.67
Debt-free, Cash-free Net Working Capital (DFCFNWC)	118	122	223	220	208	219	222	206	198	179
Debt-free Net Working Capital (DFNWC)	169	172	272	258	241	256	251	235	231	265
Net Working Capital (NWC)	169	172	272	258	241	255	248	230	224	265
Net Nonoperating Expense (NNE)	6.67	-0.67	19	14	12	9.35	15	16	14	21
Net Nonoperating Obligations (NNO)	-52	-51	-4.97	13	36	57	89	89	86	71
Total Depreciation and Amortization (D&A)	8.32	8.16	26	24	22	24	19	19	20	30
Debt-free, Cash-free Net Working Capital to Revenue	25.37%	26.41%	42.02%	36.75%	31.04%	29.35%	29.26%	26.73%	25.29%	22.38%
Debt-free Net Working Capital to Revenue	36.51%	37.41%	51.46%	43.04%	36.08%	34.41%	33.15%	30.48%	29.45%	33.10%
Net Working Capital to Revenue	36.51%	37.41%	51.46%	43.04%	36.08%	34.24%	32.73%	29.87%	28.65%	33.10%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.53)	($0.35)	($1.71)	($1.07)	($0.77)	($0.57)	($0.95)	($0.88)	($0.71)	($0.76)
Adjusted Weighted Average Basic Shares Outstanding	20.09M	20.05M	35.73M	36.76M	37.25M	36.73M	37.74M	38.02M	38.49M	38.13M
Adjusted Diluted Earnings per Share	($0.53)	($0.35)	($1.71)	($1.07)	($0.77)	($0.57)	($0.95)	($0.88)	($0.71)	($0.76)
Adjusted Weighted Average Diluted Shares Outstanding	20.09M	20.05M	35.73M	36.76M	37.25M	36.73M	37.74M	38.02M	38.49M	38.13M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	20.01M	36.46M	36.54M	36.74M	36.76M	37.41M	37.53M	38.17M	38.21M	39.02M
Normalized Net Operating Profit after Tax (NOPAT)	-4.05	-7.73	-42	-26	-17	-13	-21	-17	-13	-8.03
Normalized NOPAT Margin	-3.55%	-6.32%	-23.86%	-13.71%	-9.30%	-6.44%	-10.89%	-8.78%	-6.73%	-3.73%
Pre Tax Income Margin	-8.22%	-5.72%	-34.43%	-20.28%	-15.43%	-11.03%	-18.65%	-16.29%	-13.55%	-13.78%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-32.83	-29.51	-45.80	-28.95	-17.01	-3.90	-6.72	-5.55	-4.11	-0.99
NOPAT to Interest Expense	-14.62	-33.76	-32.43	-20.25	-10.86	-2.85	-4.51	-3.53	-2.54	-0.54
EBIT Less CapEx to Interest Expense	-51.34	-60.08	-54.70	-38.71	-30.89	-7.53	-9.03	-7.44	-5.13	-1.64
NOPAT Less CapEx to Interest Expense	-33.13	-64.33	-41.33	-30.01	-24.74	-6.48	-6.82	-5.42	-3.56	-1.19
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	-17.77%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	-17.77%	0.00%	0.00%	0.00%	0.00%

Financials Breakdown Chart

Key Financial Trends

Orthofix Medical (OFIX) shows a mix of top-line resilience and ongoing profitability challenges in the latest four quarters. Below are the key takeaways, sorted with positives first, then neutral items, then negatives.

Q4 2024 revenue rose to 215,657,000, up from 196,606,000 in Q3 2024, indicating improved top-line momentum.
Gross margin remained solid, around 68%–69% across 2024, with Q4 2024 gross profit of 148,841,000 on 215,657,000 in revenue.
Operating cash flow turned positive by Q3 2024 and improved further in Q4 2024 to 23,730,000, signaling better cash conversion from operations.
Financing activity in Q4 2024 provided a liquidity lift via debt issuance (~157,600,000) and modest equity issuance, contributing to a net cash inflow for the quarter.
Liquidity remained solid at year-end 2024, with current assets around 386–401 million and current liabilities around 151–162 million, keeping a healthy 2.3x–2.6x current ratio.
Leverage is modest but rising, with long-term debt around 112–115 million and total liabilities roughly 336–342 million, while equity hovered around 526–546 million.
Equity issuances occurred in 2024 (several million dollars across quarters), primarily bolstering cash without reversing the ongoing profitability shortfall.
Net income remained negative in every quarter, with Q4 2024 continuing losses at -29,146,000 and an EPS of -0.76 for the period.
Investing cash flows were consistently negative, reflecting ongoing capital expenditures and modest acquisitions (investing activities commonly in the mid single-digit millions per quarter).
Earnings per share stayed in negative territory (Q4 2024 basic and diluted EPS at -0.76) with a weighted average share count around 38–39 million, underscoring ongoing profitability challenges.

05/14/26 06:34 AM ETAI Generated. May Contain Errors.

Orthofix Medical Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Orthofix Medical's financial year ends in December. Their financial year 2024 ended on December 31, 2024.

Orthofix Medical's net income appears to be on an upward trend, with a most recent value of -$126.00 million in 2024, rising from -$19.75 million in 2022. The previous period was -$151.40 million in 2023. See Orthofix Medical's forecast for analyst expectations on what's next for the company.

Orthofix Medical's total operating income in 2024 was -$84.62 million, based on the following breakdown:

Total Gross Profit: $545.89 million
Total Operating Expenses: $630.50 million

Over the last 2 years, Orthofix Medical's total revenue changed from $460.71 million in 2022 to $799.49 million in 2024, a change of 73.5%.

Orthofix Medical's total liabilities were at $390.17 million at the end of 2024, a 19.5% increase from 2023, and a 220.4% increase since 2022.

In the past 2 years, Orthofix Medical's cash and equivalents has ranged from $33.11 million in 2023 to $83.24 million in 2024, and is currently $83.24 million as of their latest financial filing in 2024.

Over the last 2 years, Orthofix Medical's book value per share changed from 16.84 in 2022 to 13.17 in 2024, a change of -21.8%.

Related Companies

Financial statements for NASDAQ:OFIX last updated on 4/6/2025 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Orthofix Medical (OFIX) Financials

Financials Breakdown Chart

Key Financial Trends

Orthofix Medical Financials - Frequently Asked Questions

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Orthofix Medical (OFIX) Financials

Annual Income Statements for Orthofix Medical

Quarterly Income Statements for Orthofix Medical

Annual Cash Flow Statements for Orthofix Medical

Quarterly Cash Flow Statements for Orthofix Medical

Annual Balance Sheets for Orthofix Medical

Quarterly Balance Sheets for Orthofix Medical

Annual Metrics And Ratios for Orthofix Medical

Quarterly Metrics And Ratios for Orthofix Medical

Financials Breakdown Chart

Key Financial Trends

Orthofix Medical Financials - Frequently Asked Questions

When does Orthofix Medical's fiscal year end?

How has Orthofix Medical's net income changed over the last 2 years?

What is Orthofix Medical's operating income?

How has Orthofix Medical's revenue changed over the last 2 years?

How much debt does Orthofix Medical have?

How much cash does Orthofix Medical have?

How has Orthofix Medical's book value per share changed over the last 2 years?

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools